RNS Number : 8232Q
Pharma C Investments PLC
30 June 2022

30 June 2022

Pharma C Investments Plc

("Pharma C" or the "Company")

Issue of Equity

Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder in the medical cannabis industry, is pleased to announce that is has raised £200,000 before expenses by way of a subscription for 80 million new ordinary shares at a price of 0.25p per share ("the Subscription"). The proceeds of the Subscription will be used to provide the Company with additional working capital.

Application will be made for them to be admitted to trading on AQSE, which is expected to be on or around 8 July 2022.

The new ordinary shares will rank pari passu with the existing ordinary shares of the Company. Following the issue of the new ordinary shares, the Company's issued share capital will comprise 349,857,144 ordinary shares of 0.1p (including the 80 million new ordinary shares).

The above figure of 349,857,144 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Directors of Pharma C Investments plc take responsibility for this announcement.

This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).

- Ends -

Gavin Sathianathan, Investment Strategy Director, Pharma C Investments

gavin@pharmacinvestments.com

David Coffman / Lucy Bowden

Novum Securities

(AQSE Corporate Adviser)

Tel: +44 207 399 9429

About Pharma C

Pharma C Investments is an investment vehicle targeting the legal medicinal cannabis industry globally. The Company is seeking to identify breakout companies within the legal markets with a particular focus on the UK, EU and Israel and will provide capital, strategic insights and operational support. Pharma C is run by cannabis entrepreneurs who understand the unique challenges of the legal cannabis industry and thus can provide invaluable support and expertise for growing companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXZZGFVLGNGZZG